Melatonin-tuned mRNA-loaded lipid nanoparticles enhance NRF2-mediated mesenchymal stem cell therapy for pulmonary fibrosis.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 42580161.
- Also identified by DOI 10.1016/j.biomaterials.2026.124531.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pulmonary fibrosis is characterized by persistent oxidative stress and excessive extracellular matrix deposition, yet effective therapeutic strategies remain limited. Here, we report a nanoengineering strategy that integrates melatonin and Nrf2 mRNA within lipid nanoparticle (LNPs) to functionally engineer mesenchymal stem cells (MSCs) for redox-targeted antifibrotic therapy. Molecular dynamics simulations and membrane fluidity analyses revealed that melatonin modulates lipid packing in cholesterol-rich LNP membranes, increasing membrane fluidity and facilitating endosomal escape, thereby improving cytosolic mRNA delivery. This membrane-level tuning enabled efficient Nrf2 expression and promoted an antioxidant phenotype in the engineered MSCs. These therapeutic LNP (TN)-engineered MSCs exhibited enhanced cytoprotective and antifibrotic activities in epithelial injury models and in a bleomycin-induced pulmonary fibrosis mouse model. The therapeutic effects were associated with suppression of epithelial-mesenchymal transition and extracellular matrix remodeling. Collectively, this study establishes melatonin-driven membrane modulation as an effective strategy to enhance LNP-mediated mRNA delivery and enable functional engineering of MSCs for redox-targeted regenerative therapy.